Skip to main content

Table 6 Distribution of mouth opening, tongue protrusion, cheek flexibility according to group in different time periods

From: Effectiveness of Pentoxifylline in the treatment of oral submucous fibrosis patients: a case-control study

CLINICAL EXAMINATION

 

Group

N

Mean

Std. Deviation

U value

P value

MOUTH OPENING (mm)

Baseline

Pentoxyfylline

40

26.7906

7.85162

  

Placebo

40

25.7500

7.93116

0.527

0.600

1st Month

Pentoxyfylline

40

27.8563

7.69147

  

Placebo

40

26.7188

7.34950

0.605

0.547

2nd Month

Pentoxyfylline

40

28.4484

7.82333

  

Placebo

40

26.9375

7.35258

0.796

0.429

3rd Month

Pentoxyfylline

40

29.1313

7.87435

  

Placebo

40

26.9688

7.32862

1.137

0.260

TONGUE PROTRUSION

Baseline

Pentoxyfylline

40

31.2813

8.48997

  

Placebo

40

31.0313

9.62686

0.110

0.913

1st Month

Pentoxyfylline

40

33.1250

8.71317

  

Placebo

40

32.6250

9.95717

0.214

0.831

2nd Month

Pentoxyfylline

40

34.3750

8.85274

  

Placebo

40

33.7813

10.16869

0.249

0.804

3rd Month

Pentoxyfylline

40

34.7500

8.90451

  

Placebo

40

34.1250

10.11785

0.262

0.794

Baseline

Pentoxyfylline

40

.8856

.18243

  

CHEEK FLEXIBILITY

Placebo

40

.9348

.22551

0.958

0.342

1st Month

Pentoxyfylline

40

.9135

.18642

  

Placebo

40

.9401

.22707

0.511

0.611

2nd Month

Pentoxyfylline

40

.9144

.19621

  

Placebo

40

.9441

.22840

0.557

0.579

3rd Month

Pentoxyfylline

40

3.8575

16.63277

  

Placebo

40

.9467

.22938

0.990

0.326

Back to article page

Applied Cancer Research

ISSN: 1980-5578